Orladeyo Pellet
Product Images NDC 72769-115

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Orladeyo (NDC 72769-115). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biocryst Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Orladeyo 01)

Chemical structure diagram of berotralstat hydrochloride, the active ingredient in Orladeyo capsules, showing molecular bonds and atomic groups including fluorine, cyano, and trifluoromethyl substituents.*

FDA Label Image

Figure 1 (Orladeyo 02)

A chart titled 'Recommendation' showing geometric mean ratios and 90% confidence intervals for various CYP substrates and transporters interacting with Orladeyo. It compares AUC and Cmax values for drugs metabolized by CYP3A4, CYP2D6, CYP2C9, CYP2C19, P-gp, and BCRP, with corresponding dosing recommendations. The bottom note specifies Orladeyo dosages used in digoxin and rosuvastatin studies.*

FDA Label Image

Figure 2 (Orladeyo 03)

A line graph showing mean investigator-confirmed attack rates per month over six months for Orladeyo capsules at 110 mg and 150 mg doses compared to placebo. The x-axis represents time in months from baseline to six months, and the y-axis indicates attack rates. Data points include error bars reflecting SEM. Orladeyo 150 mg shows the lowest attack rates, followed by 110 mg, with placebo having the highest rates throughout the period.*

FDA Label Image

Principal Display Panel (150 mg Capsule Blister Card Shellpack Carton)

Packaging label for Orladeyo 150 mg capsules (berotralstat), an oral prescription drug. The label states it contains 28 capsules, a 28-day supply divided into 4 shellpacks each with a 7-capsule blister card. The labeler is BioCryst Pharmaceuticals, Inc. The label includes the NDC 72769-101-01 and relevant usage information.*

FDA Label Image

Principal Display Panel (110 mg Capsule Blister Card Shellpack Carton)

Packaging label for Orladeyo capsules 110 mg by BioCryst Pharmaceuticals, Inc. The box contains 28 oral capsules supplied as 4 shellpacks, each with a 7-capsule blister card. The label indicates prescription use only and displays the NDC 72769-102-01 along with manufacturer and contact information.*

FDA Label Image

Principal Display Panel (72 mg Pellet Packet Wallet Carton)

Packaging label for Orladeyo (berotralstat) oral pellets, 72 mg per packet, by BioCryst Pharmaceuticals Inc. The carton contains 28 packets arranged in 4 wallets of 7 unit-dose packets each, with each packet containing 72 mg of berotralstat. The label includes storage instructions and safety warnings to keep out of the reach of children.*

FDA Label Image

Principal Display Panel (96 mg Pellet Packet Wallet Carton)

Packaging label for Orladeyo (berotralstat) oral pellets, 96 mg per packet. The carton contains 28 packets, each with 96 mg of berotralstat. The label indicates it is a prescription drug distributed by BioCryst Pharmaceuticals Inc. Dosage form is oral pellets in unit-dose packets. The label includes storage instructions and a barcode.*

FDA Label Image

Principal Display Panel (108 mg Pellet Packet Wallet Carton)

Orladeyo 108 mg oral pellets carton label for packets. The packaging states the active ingredient berotralstat, with 108 mg per packet. The carton contains 28 packets, arranged as 4 wallets each with 7 unit-dose packets. The labeler is BioCryst Pharmaceuticals Inc. Storage instructions and a safety warning to keep out of reach of children are also visible.*

FDA Label Image

Principal Display Panel (132 mg Pellet Packet Wallet Carton)

Packaging label for Orladeyo (berotralstat) oral pellets, with a strength of 132 mg per packet. The label indicates the product is supplied by BioCryst Pharmaceuticals Inc. The carton contains 28 packets, each packet providing a 28-day supply with unit-dose packets. Storage instructions and prescription-only designation are visible.*

FDA Label Image

Principal Display Panel (150 mg Pellet Packet Wallet Carton)

Orladeyo 150 mg per packet (berotralstat oral pellets) packaging carton label. The label shows the product name, dosage strength of 150 mg per packet, and that it contains oral pellets. The labeler is BioCryst Pharmaceuticals Inc. The carton contains 28 packets, each with 150 mg dose, stored in 4 wallets with 7 unit-dose packets each.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.